Form 13-F position report

PRAXIS PRECISION MEDICINES I

Reported by STATE STREET CORPORATION

PRAX CUSIP 74006W207 Manager CIK 0000093751

Reported 1,026,443 shares, up 142,205 (16.1%) from the prior quarter.

Reported value 20.6%; share count 16.1% vs. the prior quarter.

Added
% of reported 13F value 0.01% This manager · Q2 2026
Shares 1,026,443 Quarter-end amount reported
Reported value $343,656,004 Fair value at quarter end
Consecutive quarters held 11 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-12-31 684174
2024-03-31 2715878
2024-06-30 33879713
2024-09-30 45434965
2024-12-31 59155689
2025-03-31 27911667
2025-06-30 29354811
2025-09-30 48076724
2025-12-31 260024049
2026-03-31 284892641
2026-06-30 343656004
2026-09-30 304148963

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for PRAXIS PRECISION MEDICINES I held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 1,044,423 +17,980 (1.8%) < 0.01% $304,148,963 2026-11-12
Q2 2026 Added 1,026,443 +142,205 (16.1%) 0.01% $343,656,004 2026-08-07
Q1 2026 Added 884,238 +2,023 (0.2%) < 0.01% $284,892,641 2026-05-15
Q4 2025 Reduced 882,215 -24,893 (-2.7%) < 0.01% $260,024,049 2026-02-13
Q3 2025 Added 907,108 +209,015 (29.9%) < 0.01% $48,076,724 2025-11-14
Q2 2025 Reduced 698,093 -38,946 (-5.3%) < 0.01% $29,354,811 2025-08-14
Q1 2025 Reduced 737,039 -31,616 (-4.1%) < 0.01% $27,911,667 2025-05-15
Q4 2024 Reduced 768,655 -20,969 (-2.7%) < 0.01% $59,155,689 2025-02-14
Q3 2024 Reduced 789,624 -29,518 (-3.6%) < 0.01% $45,434,965 2024-11-14
Q2 2024 Added 819,142 +774,634 (1740.4%) < 0.01% $33,879,713 2024-08-14
Q1 2024 Added 44,508 +13,800 (44.9%) < 0.01% $2,715,878 2024-05-15
Q4 2023 New 30,708 +30,708 (0.0%) < 0.01% $684,174 2024-02-14

Who else reported the position

352 managers reported PRAXIS PRECISION MEDICINES I for Q2 2026.

Managers reporting PRAXIS PRECISION MEDICINES I in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Jupiter Topco LLC New 3,421,374 +3,421,374 0.47% $1,145,994,051 1 qtr
FMR LLC Added 2,316,907 +155,964 0.03% $775,677,279 11 qtrs
BlackRock Inc Reduced 2,292,585 -32,344 0.01% $767,534,532 8 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 2,035,986 0 10.23% $681,627,753 10 qtrs
BAKER BROS ADVISORS LP Unchanged 1,753,198 0 2.94% $586,953,158 10 qtrs
Orbis Allan Gray Ltd Reduced 1,529,788 -942,692 1.76% $512,157,724 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 1,335,185 +578,437 0.02% $447,006,586 2 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 1,235,299 +13,355 < 0.01% $413,565,752 2 qtrs
STATE STREET CORPORATION This report Added 1,026,443 +142,205 0.01% $343,656,004 11 qtrs
ADAGE CAPITAL PARTNERS GP L L C Added 1,015,480 +199,741 0.48% $339,972,549 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 07, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
147,865
Shared
200
None
878,378

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.